Transdermal Skin Patches Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 8.92 Billion |
| Market Size (2029) | USD 11.33 Billion |
| CAGR (2024 - 2029) | 4.87 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Transdermal Skin Patches Market Analysis
The Transdermal Skin Patches Market size is estimated at USD 8.92 billion in 2024, and is expected to reach USD 11.33 billion by 2029, growing at a CAGR of 4.87% during the forecast period (2024-2029).
The COVID-19 outbreak has impacted the transdermal skin patches market. These patches enable safe, reproducible, and controlled administration of drugs to a defined skin microenvironment. Therefore, researchers working on a potential vaccine against the new COVID-19 strain explored the uses of a fingertip-sized skin patch for delivery. For instance, an article published in May 2020 stated that researchers at the University of Pittsburgh Medical Center and the University of Pittsburgh attempted to develop a microneedle array (MNA), a fingertip-sized patch with 400 microscopic needles that could inject spike protein fragments into the skin.
Additionally, in January 2021, a team at the Swansea University Institute for Innovative Materials, Processing, and Numerical Technologies (IMPACT) produced the COVID-19 smart vaccine patch using microneedles (MNs). The primary goal of this project was to create a prototype of the smart vaccine delivery device that could not only deliver the COVID-19 vaccine transdermal but also monitor biomarkers in the skin compartment in a minimally invasive way, offering real-time information on the efficacy of the vaccination. Hence, COVID-19 has a significant impact on the studied market.
Certain factors attributing to the market growth are the increasing advantages of transdermal medicine over oral and ingesting medications and increasing funding and investments in drug development.
Oral medications can have gastrointestinal adverse effects like nausea or upset stomach. However, digestive side effects can usually be prevented with transdermal patches. For instance, according to an article published in February 2022, it has been observed that the transdermal patch delivers medication directly to the bloodstream through the skin, bypassing the digestive tract and any potential side effects. Transdermal patches, therefore, offer a non-invasive, painless method of drug administration with the added benefit of delivering a continuous therapeutic dose for a specified period. This is expected to increase its adoption among the target population, propelling market growth.
These patches also treat migraine, hormones, pain, cardiovascular diseases, neurology disease, and smoking cessation. Currently, the demand for the transdermal route of the drug delivery system is increasing due to decreased dose frequency, greater bioavailability, reduced side effects, and drug input cessation at any time by removing the patch.
Additionally, the increasing use of tobacco in the form of cigarettes has increased globally over time, creating a healthcare burden. For instance, as per the data published by the WHO data in May 2022, it has been observed that 22.3% of the global population used tobacco in 2021, of which men accounted for 36.7% of the total male population, and women accounted for 7.8% of the world's women population. Therefore, with the increasing number of smokers globally, the usage of nicotine transdermal skin patches and the rising number of patients is expected to boost the market studied.
Furthermore, the growing company's focus on adopting various business strategies such as collaborations, acquisitions, product launches, and others to enter the transdermal patches market contributes to market growth. For instance, in December 2021, Luye Pharma Group announced that their subsidiary Luye Pharma Switzerland AG has agreed with Changchun GeneScience Pharmaceutical Co. Ltd (Gensci) of China, under which the company grants Gensci the exclusive commercialization rights of Rivastigmine Single-Day Transdermal Patch (Rivastigmine SD) and Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) on the Chinese mainland. Additionally, in September 2021, ImQuest Biosciences launched its antiretroviral (ARV) transdermal delivery patch. The device utilizes a polymeric patch and film, which releases the drug into the skin over seven days.
Moreover, the increasing awareness among the people for their health and the increasing expendable income leads to high expenditure on healthcare. Also, governments across the globe are investing heavily in drug research. For instance, in October 2021, USFDA awarded 11 grants to clinical trials to develop new medical products for rare disease treatments. Additionally, from the data published by the Canadian government in January 2022, it was found that the public and private sectors invested USD 226,246.5 million and USD 75,208.3 million in developing pharmaceutical drugs, respectively. Such government investments are expected to create opportunities for transdermal medicines or patches, thereby boosting the market growth.
However, the inability of the skin to absorb a range of active substances is expected to hinder the market growth over the forecast period.
Transdermal Skin Patches Market Trends
This section covers the major market trends shaping the Transdermal Skin Patches Market according to our research experts:
Pain Relief Segment Expects to Register a High CAGR in the Transdermal Skin Patches Market Over the Forecast Period
The pain-relief segment is expected to witness significant growth in the transdermal patches market over the forecast period.
The factors attributing to the segment growth are the rising prevalence of pain-related disorders, such as diabetic neuropathy, rheumatoid arthritis, osteoarthritis, migraine, and other diseases among the population. For instance, from an article published in February 2022, it was observed that back pain is a common ailment among adults and up to 23% of the total population of the world experience chronic low back pain. In addition, as per the same source, the target group also revealed a one-year recurrence rate of 24% to 80%, and some estimates of lifetime prevalence are as high as 84% in the adult population. Thus, the rising burden of back pain among the population is anticipated to increase the demand for pain relief patches, thereby bolstering segment growth.
Furthermore, according to the Migraine Research Foundation data updated in 2021, migraine is an extraordinarily prevalent neurological disease affecting about 39 million men, women, and children in the United States and 1 billion globally. Migraine is considered the third-most prevalent illness in the world, which is expected to raise the demand for effective patches that helps in relieving pain from migraine headaches, thereby propelling the market growth.
Moreover, the rising company activities in developing pain relief patches also contribute to the market growth over the forecast period. For instance, in November 2021, NEXGEL launched its MEDAGEL Migraine Relief Patch, developed using NEXGEL's unique hydrogel technology. The patch provides instant and long-lasting cooling relief from migraines, hormonal headaches, and fevers by pulling heat away from the body.
Thus, owing to the factors mentioned above, the segment is expected to grow significantly during the forecast period.
North America Dominates the Market and is Expected to Continue Dominating During the Forecast Period
North America is expected to witness significant growth in the transdermal patches market over the forecast period.
The factors attributing to the market growth are the presence of key players and established healthcare infrastructure. In addition, the rising government initiatives and an increase in the number of research partnerships are also contributing to the market growth.
In North America, the United States is expected to hold the maximum share of the transdermal patches market due to supportive healthcare policies, many patients suffering from pain and other chronic diseases, and a developed healthcare market.
The rising number of smokers in the region is expected to increase the demand for nicotine transdermal patches, which is expected to increase market growth. For instance, from the data published by CDC in March 2022, it has been observed that about 34.0% of high school students (5.22 million) and 11.3% of middle school students (1.34 million) reported ever using a tobacco product (i.e., electronic cigarettes [e-cigarettes], cigarettes, cigars, smokeless tobacco, hookahs, pipe tobacco, heated tobacco products, nicotine pouches, and bidis [small brown cigarettes wrapped in a leaf. Additionally, e-cigarettes are the most often used tobacco product from the same source, followed by cigarettes, cigars, smokeless tobacco, hookahs, nicotine pouches, heated tobacco products, and pipe tobacco among high school and middle school students.
According to the Canadian Lung Association 2021, tobacco is the leading cause of preventable disease and death in Canada. Each year, an estimated 48,000 Canadians die because of smoking. Countless others suffer from long-term illnesses. Despite public health education and preventive efforts, about 15% of Canadians continue to smoke, which has increased the widespread availability of drugs. The advent of new innovative drugs, such as transdermal patches, has accelerated the market's growth.
Additionally, the rising incidence of cancers, including breast and prostate cancer, is probably going to accelerate market growth greatly. For instance, according to the GLOBOCAN 2020 report, 195,499 cancer cases were reported in Mexico in 2020, with breast and prostate cancers being the most common among the population. Furthermore, according to Globocan 2020, the incidence of cancer in Mexico is predicted to rise to 254,665 cases by 2030 and 323,432 cases by 2040. Thus, the growing burden of cancer among the population is expected to increase the demand for transdermal patches with drug nanoparticles that relieve pain from cancer therapy, propelling the market growth.
Furthermore, various initiatives taken by the government authority and other organizations in Mexico to prevent smoking are likely to support the market's growth. For instance, in April 2022, Cancun launched a new campaign aimed at United States visitors. In collaboration with the General Communication Coordination (CGC), local authorities aimed toward international tourists dubbed "Be a part of the solution. ". Thus, such initiatives are created awareness among individuals and drive the demand for transdermal skin patches in the country.
Moreover, the rising product launches and business strategies adopted by the companies to withhold their market position also contribute to market growth. For instance, in April 2021, BASF launched 'Sacred Patch,' a new active skincare ingredient that could help boost emotional well-being. Similarly, in 2020, Amneal Pharmaceuticals Inc. received the Abbreviated New Drug Application (ANDA) approval from the USFDA for a generic version of Butrans (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr, and 20 mcg/hr.
Thus, owing to the factors mentioned above, the market is expected to grow significantly during the forecast period.
Transdermal Skin Patches Industry Overview
The transdermal skin patches market is moderately competitive. The key players are focused on adopting product innovations, product launches and approvals, R&D investment for advancements in transdermal patches, and mergers and acquisitions as their developmental strategies to sustain the competitive market environment. Some major companies in the market are Teva Pharmaceuticals USA Inc., Novartis AG, Teikoku Pharma USA Inc., Mylan Inc., and 3M.
Transdermal Skin Patches Market Leaders
-
Teva Pharmaceuticals USA Inc.
-
Novartis AG
-
Teikoku Pharma USA, Inc.
-
Viatris, Inc.
-
Johnson & Johnson
*Disclaimer: Major Players sorted in no particular order
Transdermal Skin Patches Market News
- In September 2022, Corium launched its Adlarity (donepezil transdermal system) for prescription use in the US Adlarity, a once-weekly patch, delivers consistent doses of donepezil through the skin. It could treat patients with mild, moderate, or severe dementia of Alzheimer's type
- In April 2022, Luye Pharma Group announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) had accepted the Marketing Authorization Application (MAA) for the company's investigational Rivastigmine Twice Weekly Transdermal Patch that was indicated for treating Alzheimer's disease of mild to moderate symptoms.
Transdermal Skin Patches Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Advantages of Transdermal Medicine Over Oral and Ingesting Medications
- 4.2.2 Increasing Funding and Investments in Drug Research
-
4.3 Market Restraints
- 4.3.1 Inability of the Skin to Absorb a Range of Active Substance
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Type
- 5.1.1 Single-layer Drug-in-Adhesive
- 5.1.2 Multi-layer Drug-in-Adhesive
- 5.1.3 Matrix
- 5.1.4 Other Types
-
5.2 By Application
- 5.2.1 Pain Relief
- 5.2.2 Smoking Reduction and Cessation Aid
- 5.2.3 Overactive Bladder
- 5.2.4 Hormonal Therapy
- 5.2.5 Other Applications
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East & Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East & Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Teva Pharmaceutical Industries Ltd
- 6.1.2 Novartis AG
- 6.1.3 Teikoku Pharma USA Inc. (Teikoku Seiyaku Co. Ltd)
- 6.1.4 Viatris Inc.
- 6.1.5 Johnson & Johnson
- 6.1.6 Luye Pharma Group
- 6.1.7 Purdue Pharma Manufacturing LP
- 6.1.8 Henan Lingrui Pharmaceutical Ltd
- 6.1.9 Samyang Biopharmaceuticals Corp. (Samyang Holdings)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityTransdermal Skin Patches Industry Segmentation
As per the scope of the report, the transdermal patch is a type of transdermal technology. It is a medicated adhesive patch that is placed on the skin to deliver a precise dose of medication. These patches deliver medicine dosage through the skin using a diffusion technique, which gets released into the bloodstream over a long period. The transdermal skin patches market is segmented by type (single-layer drug-in-adhesive, multi-layer drug-in-adhesive, matrix, and other types), application (pain relief, smoking reduction, and cessation aid, overactive bladder, hormonal therapy, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD million for the above segments.
| By Type | Single-layer Drug-in-Adhesive | |
| Multi-layer Drug-in-Adhesive | ||
| Matrix | ||
| Other Types | ||
| By Application | Pain Relief | |
| Smoking Reduction and Cessation Aid | ||
| Overactive Bladder | ||
| Hormonal Therapy | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East & Africa | GCC |
| South Africa | ||
| Rest of Middle East & Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Transdermal Skin Patches Market Research FAQs
How big is the Transdermal Skin Patches Market?
The Transdermal Skin Patches Market size is expected to reach USD 8.92 billion in 2024 and grow at a CAGR of 4.87% to reach USD 11.33 billion by 2029.
What is the current Transdermal Skin Patches Market size?
In 2024, the Transdermal Skin Patches Market size is expected to reach USD 8.92 billion.
Who are the key players in Transdermal Skin Patches Market?
Teva Pharmaceuticals USA Inc., Novartis AG, Teikoku Pharma USA, Inc., Viatris, Inc. and Johnson & Johnson are the major companies operating in the Transdermal Skin Patches Market.
Which is the fastest growing region in Transdermal Skin Patches Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Transdermal Skin Patches Market?
In 2024, the North America accounts for the largest market share in Transdermal Skin Patches Market.
What years does this Transdermal Skin Patches Market cover, and what was the market size in 2023?
In 2023, the Transdermal Skin Patches Market size was estimated at USD 8.51 billion. The report covers the Transdermal Skin Patches Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Transdermal Skin Patches Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Transdermal Skin Patches Industry Report
The Global Transdermal Skin Patches Market is segmented by type and application across various geographies. The market analysis includes single-layer drug-in-adhesive, multi-layer drug-in-adhesive, matrix, and other types. Applications cover pain relief, smoking reduction and cessation aid, overactive bladder, hormonal therapy, and other uses. The market forecast provides a comprehensive overview of the market growth, market size, and market share.
The industry report offers valuable insights into the market trends and market leaders, focusing on industry statistics and market segmentation. The industry outlook highlights the expected market growth and market value, providing a detailed market review. The market data and market predictions are crucial for understanding the market overview and market forecast.
Additionally, the report includes industry research and industry sales information, offering a thorough industry analysis. The market outlook and market review provide a clear picture of the market dynamics, supported by industry trends and industry size data. The report example and report PDF are available for a deeper dive into the market research and market forecast.
Overall, the industry reports and market leaders' insights are essential for understanding the market trends and industry outlook. The report highlights the significance of market segmentation and market value in driving market growth. The market forecast and market review offer a comprehensive understanding of the market dynamics, supported by industry analysis and industry statistics. The report PDF and report example provide additional resources for further research and analysis.
